![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Real-world utilization of the new fixed-dose combination elbasvir/grazoprevir in adult patients with chronic hepatitis C in Canada: Z-PROFILE study
|
|
|
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Edward Tam1, Chris Fraser2, Julie Tremblay3, Brian Conway4, Benoit Trottier5, Alnoor Ramji6, Sergio Borgia7, Kris Stewart8, Janie B. Trepanier9, Youb Chalabi9
1LAIR Centre, BC, Canada; 2The Cool Aid Community Health Centre, BC, Canada; 3Centre Sida Amitie, QC, Canada; 4Vancouver Infectious Diseases Centre, BC, Canada; 5Clinique Medicale du Quartier Latin, QC, Canada; 6GI Research Institute (GIRI), Gastroenterology Division, BC, Canada; 7William Osler Health System, ON, Canada; 8Saskatchewan Infectious Disease Care Network, SK, Canada; 9Merck Canada Inc., QC, Canada.
![0428171](../images/042817/042817-5/0428171.gif)
![0428172](../images/042817/042817-5/0428172.gif)
![0428173](../images/042817/042817-5/0428173.gif)
![0428174](../images/042817/042817-5/0428174.gif)
![0428175](../images/042817/042817-5/0428175.gif)
![0428176](../images/042817/042817-5/0428176.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|